Wang et al. reported that inhibiting the Nrf2/glutathione peroxidase 4 (GPX4) pathway promotes ferroptosis, thereby exacerbating doxorubicin‐induced cardiomyopathy.11 The gene discussed is GPX4; the disease is cardiomyopathy.